495 related articles for article (PubMed ID: 9815837)
1. Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy.
Foxall PJ; Singer JM; Hartley JM; Neild GH; Lapsley M; Nicholson JK; Souhami RL
Clin Cancer Res; 1997 Sep; 3(9):1507-18. PubMed ID: 9815837
[TBL] [Abstract][Full Text] [Related]
2. Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children.
Goren MP; Epelman S; Bush DA
Cancer Chemother Pharmacol; 2004 Sep; 54(3):237-40. PubMed ID: 15184993
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children.
Loebstein R; Atanackovic G; Bishai R; Wolpin J; Khattak S; Hashemi G; Gobrial M; Baruchel S; Ito S; Koren G
J Clin Pharmacol; 1999 May; 39(5):454-61. PubMed ID: 10234592
[TBL] [Abstract][Full Text] [Related]
4. [Ifosfamide induced encephalopathy: 15 observations].
Dufour C; Grill J; Sabouraud P; Behar C; Munzer M; Motte J; Oberlin O; Paci A; Hartmann O
Arch Pediatr; 2006 Feb; 13(2):140-5. PubMed ID: 16364615
[TBL] [Abstract][Full Text] [Related]
5. Mesna excretion and ifosfamide nephrotoxicity in children.
Goren MP; Pratt CB; Meyer WH; Wright RK; Dodge RK; Viar MJ
Cancer Res; 1989 Dec; 49(24 Pt 1):7153-7. PubMed ID: 2510931
[TBL] [Abstract][Full Text] [Related]
6. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.
Pelgrims J; De Vos F; Van den Brande J; Schrijvers D; Prové A; Vermorken JB
Br J Cancer; 2000 Jan; 82(2):291-4. PubMed ID: 10646879
[TBL] [Abstract][Full Text] [Related]
7. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System.
Stöhr W; Paulides M; Bielack S; Jürgens H; Treuner J; Rossi R; Langer T; Beck JD
Pediatr Blood Cancer; 2007 Apr; 48(4):447-52. PubMed ID: 16628552
[TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy.
Aeschlimann C; Küpfer A; Schefer H; Cerny T
Drug Metab Dispos; 1998 Sep; 26(9):883-90. PubMed ID: 9733667
[TBL] [Abstract][Full Text] [Related]
9. Ongoing clinical studies of ifosfamide for pediatric cancer in the United States.
Pratt CB
Semin Oncol; 1996 Jun; 23(3 Suppl 6):84-90. PubMed ID: 8677456
[TBL] [Abstract][Full Text] [Related]
10. Renal dysfunctions secondary to ifosfamide treatment in children.
Tokuc G; Yalçiner A; Kebudi R; Dogan S; Görgün O; Ayan I
J Exp Clin Cancer Res; 1997 Jun; 16(2):227-30. PubMed ID: 9261752
[TBL] [Abstract][Full Text] [Related]
11. Nuclear magnetic resonance spectroscopy and pattern recognition analysis of the biochemical processes associated with the progression of and recovery from nephrotoxic lesions in the rat induced by mercury(II) chloride and 2-bromoethanamine.
Holmes E; Bonner FW; Sweatman BC; Lindon JC; Beddell CR; Rahr E; Nicholson JK
Mol Pharmacol; 1992 Nov; 42(5):922-30. PubMed ID: 1435756
[TBL] [Abstract][Full Text] [Related]
12. Proton NMR spectra of urine as indicators of renal damage. Mercury-induced nephrotoxicity in rats.
Nicholson JK; Timbrell JA; Sadler PJ
Mol Pharmacol; 1985 Jun; 27(6):644-51. PubMed ID: 2860559
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant.
Howell JE; Szabatura AH; Hatfield Seung A; Nesbit SA
J Oncol Pharm Pract; 2008 Sep; 14(3):157-62. PubMed ID: 18719071
[TBL] [Abstract][Full Text] [Related]
14. High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.
Talbot SM; Rankin C; Taub RN; Balcerzak SP; Bhoopalam N; Chapman RA; Baker LH; Middleman EL; Antman KH
Cancer; 2003 Jul; 98(2):331-6. PubMed ID: 12872353
[TBL] [Abstract][Full Text] [Related]
15. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
16. A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults.
Ho PT; Zimmerman K; Wexler LH; Blaney S; Jarosinski P; Weaver-McClure L; Izraeli S; Balis FM
Cancer; 1995 Dec; 76(12):2557-64. PubMed ID: 8625085
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
[TBL] [Abstract][Full Text] [Related]
18. Ifosfamide in the treatment of pediatric malignancies.
Voûte PA; van den Berg H; Behrendt H; Michiels E; de Kraker J
Semin Oncol; 1996 Jun; 23(3 Suppl 7):8-11. PubMed ID: 8711502
[TBL] [Abstract][Full Text] [Related]
19. [Methylene blue in ifosfamide-induced encephalopathy].
Koschuth A; Späth-Schwalbe PE; Possinger K
Dtsch Med Wochenschr; 1996 Sep; 121(39):1210. PubMed ID: 8925751
[No Abstract] [Full Text] [Related]
20. Nuclear magnetic resonance and high-performance liquid chromatography-nuclear magnetic resonance studies on the toxicity and metabolism of ifosfamide.
Foxall PJ; Lenz EM; Lindon JC; Neild GH; Wilson ID; Nicholson JK
Ther Drug Monit; 1996 Aug; 18(4):498-505. PubMed ID: 8857575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]